Module 11 - IPCRC.NET
Download
Report
Transcript Module 11 - IPCRC.NET
The
EPEC-O
TM
Education in Palliative and End-of-life Care - Oncology
Project
The EPEC-O Curriculum is produced by the EPECTM Project with major funding
provided by NCI, with supplemental funding provided by the Lance Armstrong
Foundation.
E
P
E
C
EPEC – Oncology
Education in Palliative and End-of-life Care – Oncology
O
Module 3f
Symptoms –
Constipation
Constipation . . .
Straining
Hard stool
Sensation of
Incomplete evacuation
Anorectal obstruction
Fewer than 3 BM / week
12 weeks duration > 2 symptoms
. . . Constipation
Epidemiology
Impact: abdominal discomfort / pain,
nausea and vomiting
Prevalence: up to 90 % among
cancer patients treated with opioids
Prognosis: can limit prognosis if
untreated
Management always possible
Key points
1. Pathophysiology
2. Assessment
3. Management
Pathophysiology
Medications
Opioids
Calcium-channel
blockers
Anticholinergic
Decreased
motility
Ileus
Mechanical
obstruction
Metabolic
abnormalities
Spinal cord
compression
Dehydration
Autonomic
dysfunction
Malignancy
Assessment
Specifically ask about bowel function
Establish what is normal for patient
Management
General measures
Specific measures
Regular toileting
Softeners
Gastrocolic reflex
Osmotics
Activity
Stimulants
Lubricants
Large volume
enemas
Stool softeners
(detergent laxatives)
Sodium docusate
Calcium docusate
Phospho-soda enema PRN
Stimulant laxatives
Prune juice
Senna
Casanthranol
Bisacodyl
Osmotic laxatives
Lactulose or sorbitol
Milk of magnesia (other Mg salts)
Magnesium citrate
Polyethylene glycol
Lederle FA, et al. Am J Med, 1990.
Attar A, et al. Gut, 1999.
Lubricants / enemas
Glycerin suppositories
Phosphate enema
Oil retention enema
Tap water, 500 – 1,000 ml
Constipation from
opioids . . .
Occurs with all opioids
Pharmacological tolerance develops
slowly, or not at all
Dietary interventions alone usually
not sufficient
Avoid bulk-forming agents in
debilitated patients
Bagnol D, et al. Neuroscience, 1997.
. . . Constipation from
opioids
Combination stimulant / softeners
are useful first-line medications
Casanthranol + docusate sodium
Senna + docusate sodium
Prokinetic agents
Opioid antagonists
Sykes NP. Palliat Med, 2000.
E
P
E
C
Summary
O
Use comprehensive
assessment and
pathophysiology-based therapy
to treat the cause and improve
the cancer experience